Online CBT for MS-Related Depression (Deprexis)

Condition: Multiple sclerosis

Eligibility

Key Inclusion Criteria

  • At least 18 years old
  • Neurologist-confirmed diagnosis of MS
  • Self-reported depressive symptoms

Key Exclusion Criteria

  • Diagnosis of bipolar or psychosis
  • Substantial neurocognitive impairments such as dementia or autism
  • Moderate or high risk of suicide

Full Study Name

International Deprexis Trial in Multiple Sclerosis (IDEMS) - A Multi-Center, Randomized, Controlled Trial (IRB no. 45146)

Summary

The purpose of this study is to determine the effectiveness of an online program called Deprexis for the treatment of depressive symptoms in individuals with multiple sclerosis (MS). Deprexis was developed to treat depression; in this study, the program has been modified to address MS-specific depression symptoms.

Patients will be randomly assigned to one of three study groups. Group 1 will receive immediate access to Deprexis, which uses simulated dialog to engage the user in automated cognitive behavioral therapy. Group 2 will receive immediate access to Deprexis with added weekly messaging support from a therapist (DeprexisPlus). Group 3 will take part in the same clinical visits as Group 1 and Group 2 and will receive access to Deprexis after a six-month waiting period. All participants will be asked to complete questionnaires and assessments.

Phase

Phase III


Principal Investigator

Nancy Sicotte, MD

Contact